Hill-Rom (HRC) Rating Lowered to Hold at ValuEngine

Hill-Rom (NYSE:HRC) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Several other research firms have also issued reports on HRC. Zacks Investment Research lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Goldman Sachs Group initiated coverage on shares of Hill-Rom in a research note on Wednesday, April 4th. They set a “neutral” rating and a $85.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $106.00 target price (up from $105.00) on shares of Hill-Rom in a research note on Monday, April 30th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $94.00.

HRC stock opened at $91.08 on Friday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.36 and a current ratio of 1.85. Hill-Rom has a 52-week low of $71.91 and a 52-week high of $94.63. The stock has a market cap of $6.04 billion, a PE ratio of 23.60, a PEG ratio of 1.39 and a beta of 0.99.

Hill-Rom (NYSE:HRC) last posted its earnings results on Friday, April 27th. The medical technology company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.03. Hill-Rom had a net margin of 6.85% and a return on equity of 20.18%. The business had revenue of $710.50 million for the quarter, compared to analyst estimates of $707.54 million. During the same period in the prior year, the company posted $0.88 EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. sell-side analysts forecast that Hill-Rom will post 4.63 earnings per share for the current fiscal year.

In related news, SVP Deborah Rasin sold 7,590 shares of the firm’s stock in a transaction dated Thursday, April 12th. The shares were sold at an average price of $86.02, for a total value of $652,891.80. Following the transaction, the senior vice president now directly owns 14,028 shares of the company’s stock, valued at approximately $1,206,688.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Alton Shader sold 16,812 shares of the firm’s stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $93.70, for a total transaction of $1,575,284.40. Following the completion of the transaction, the senior vice president now directly owns 54,898 shares in the company, valued at $5,143,942.60. The disclosure for this sale can be found here. Insiders sold a total of 29,570 shares of company stock worth $2,697,844 over the last ninety days. 1.90% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Deutsche Bank AG lifted its stake in Hill-Rom by 103.9% in the 4th quarter. Deutsche Bank AG now owns 325,861 shares of the medical technology company’s stock valued at $27,461,000 after buying an additional 166,057 shares in the last quarter. We Are One Seven LLC purchased a new position in Hill-Rom in the 4th quarter worth approximately $188,000. Elkfork Partners LLC purchased a new position in Hill-Rom in the 4th quarter worth approximately $1,652,000. Jefferies Group LLC lifted its stake in Hill-Rom by 46.9% in the 4th quarter. Jefferies Group LLC now owns 13,532 shares of the medical technology company’s stock worth $1,141,000 after purchasing an additional 4,322 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Hill-Rom by 52.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,357 shares of the medical technology company’s stock worth $283,000 after purchasing an additional 1,156 shares in the last quarter. 81.31% of the stock is currently owned by hedge funds and other institutional investors.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply